Privately held Areteia Therapeutics announced that dexpramipexole, an oral twice-daily drug candidate, met its primary endpoint by improving lung function in a placebo-controlled Phase 3 study targeting an asthma subtype characterized by white blood cell elevation. Areteia is conducting additional Phase 3 trials to further investigate dexpramipexole's clinical benefit. This development represents a notable step toward oral alternatives to existing biologic treatments in asthma management.